Evaluation of discomfort level during bronchoscopic examination under fentanyl and midazolam for sedation

Evaluation of discomfort level during bronchoscopic examination under fentanyl and midazolam for sedation - Evaluation of discomfort level during bronchoscopic examination under fentanyl and midazolam for sedation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015577

Enrollment

Registered

2014-11-19

Start date

2014-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest and Mediastinal Diseases

Interventions

Bronchoscopic examination under fentanyl and midazolam for sedation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Patients refered to bronchoscopic examination (b) Patients refered to elective bronchoscopic examination (c) Patients that have never had bronchoscopic examination (d) Performance status(less than 3) (e) Patinets obtaining mental condition in questionnaire survey (f) Informed consent (g) Patients that take no opioid

Exclusion criteria

Exclusion criteria: (a) Contraindication for bronchoscopic examination (b) Patients that have ever had been allergic to some medicine (c) Mental difficulties in this study (d) Other presumed difficulties for patients in this study

Design outcomes

Primary

Measure	Time frame
The rate in acceptance level of re-examination (Less than 2 evaluation phases over 5 evaluation phases .We perform a questionnaire survey with a visual analogue scale after bronchoscopic examination).	—

Countries

Japan

Contacts

Public ContactDaisuke Minami

Okayama University Hospital Palliative and Supportive Medicine

d-minami@bj8.so-net.ne.jp086-235-7227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026